MOTS-c(human) acetate

MOTS-c (human) acetate 是一种可穿透血脑屏障的线粒体来源多肽,通过调节 AMPK/PGC-1α 通路增强胰岛素敏感性,并抑制叶酸循环和嘌呤从头合成、升高 AICAR 水平以激活 AMPK,进而调控 Nrf2/Keap1 抗氧化通路、抑制 NF-κB 炎症通路,同时促进线粒体生物发生和能量代谢,具有改善糖脂代谢、抗氧化应激、抗炎及神经保护作用,可用于 2 型糖尿病、创伤性脑损伤、炎症性疾病及衰老相关代谢紊乱等研究(高分辨率测序的最新进展导致发现了源自线粒体基因组的独特肽,目前已鉴定出 8 种肽:护脑素、12S tRNA-c (MOTS-c) 的线粒体开放阅读框和 6 种小肽(护脑素样肽 (SHLP1-6)),所有这些肽均从线粒体释放到细胞质中,并与延长寿命和细胞活力、减少细胞凋亡和其他有益功能相关)。
MOTS-c(human) acetate
产品编号: MS-B00371 纯度: 99.74% 分子式: C103H156N28O24S2 分子量: 2234.64
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价

产品描述

MOTS-c (human) acetate 是一种可穿透血脑屏障的线粒体来源多肽,通过调节 AMPK/PGC-1α 通路增强胰岛素敏感性,并抑制叶酸循环和嘌呤从头合成、升高 AICAR 水平以激活 AMPK,进而调控 Nrf2/Keap1 抗氧化通路、抑制 NF-κB 炎症通路,同时促进线粒体生物发生和能量代谢,具有改善糖脂代谢、抗氧化应激、抗炎及神经保护作用,可用于 2 型糖尿病、创伤性脑损伤、炎症性疾病及衰老相关代谢紊乱等研究(高分辨率测序的最新进展导致发现了源自线粒体基因组的独特肽,目前已鉴定出 8 种肽:护脑素、12S tRNA-c (MOTS-c) 的线粒体开放阅读框和 6 种小肽(护脑素样肽 (SHLP1-6)),所有这些肽均从线粒体释放到细胞质中,并与延长寿命和细胞活力、减少细胞凋亡和其他有益功能相关)。

生物实验数据

生物活性 MOTS-c (human) acetate is a mitochondria-derived peptide capable of crossing the blood-brain barrier that enhances insulin sensitivity by regulating the AMPK/PGC-1α pathway, and inhibits the folate cycle and de novo purine synthesis, elevating AICAR levels to activate AMPK, thereby modulating the Nrf2/Keap1 antioxidant pathway and suppressing the NF-κB inflammatory pathway while promoting mitochondrial biogenesis and energy metabolism; it exhibits effects of improving glucose and lipid metabolism, antioxidant stress, anti-inflammation, and neuroprotection, and can be used in research on type 2 diabetes, traumatic brain injury, inflammatory diseases, and aging-related metabolic disorders (recent advances in high-resolution sequencing have led to the discovery of unique peptides derived from the mitochondrial genome, and 8 peptides have been identified to date: humanin, the mitochondrial open reading frame of 12S tRNA-c (MOTS-c), and 6 small peptides (humanin-like peptides (SHLP1-6)), all of which are released from mitochondria into the cytoplasm and are associated with extended lifespan and cell viability, reduced apoptosis, and other beneficial functions).
IC50 & Target

AMPK

 

GLUT4

 

AICAR

 

体外研究
(In Vitro)

MOTS-c 在 5Me-THF 水平上抑制叶酸循环,导致 AICAR [5-氨基咪唑-4-甲酰胺核苷酸] 积累。MOTS-c 还会增加细胞 NAD+ 水平,而 NAD 也是核苷酸前体。
MOTS-c 是一种线粒体信号,可刺激细胞葡萄糖吸收,同时抑制呼吸。响应 MOTS-c 吸收的葡萄糖被引导至合成代谢戊糖磷酸途径 (PPP),该途径为嘌呤的合成提供碳源,而不是通过糖酵解代谢。此外,MOTS-c 还会增加肉碱穿梭机的水平,肉碱穿梭机将活性脂肪酸运送到线粒体进行 β-氧化,增加 β-氧化中间体的水平,并降低细胞内必需和非必需脂肪酸的水平,表明脂质利用率增强;稳定过表达 MOTS-c 的肌细胞也表现出葡萄糖吸收增加。

Western Blot Analysis

Cell Line: HEK293 cells
Concentration: 10 μM
Incubation Time: 24-72 h
Result: Significantly increased phosphorylation of AMPK at Thr172 and protein levels of Nrf2 and Keap1, while reducing phosphorylation of ERK, JNK, and P38.
Resulted activation of AMPK by densitometric quantification, with a 2-fold increase in p-AMPK/AMPK ratio compared to control.
Attenuated these effects by co-treatment with the AMPK inhibitor.
体内研究
(In Vivo)

小鼠注射 MOTS-c 后,骨骼肌 AMPK 被激活,其下游葡萄糖转运蛋白 GLUT4 的水平也随之升高。MOTS-c 也可能作为一种潜在的线粒体信号,介导运动诱发的线粒体兴奋反应,从而刺激生理适应并提高运动耐受性。
MOTS-c 的主要靶器官似乎是骨骼肌和脂肪。小鼠体内的 MOTS-c 水平会随着年龄的增长而下降,骨骼肌和血液循环中的水平也会随之下降,同时伴随年龄依赖性的胰岛素抵抗的出现。通过全身注射恢复老年小鼠(12 个月龄)的 MOTS-c 水平,成功逆转了年龄依赖性的骨骼肌胰岛素抵抗。

Animal Model: Male C57BL/6 mice (6-8-week-old) with controlled-cortical impact (CCI)-induced traumatic brain injury model
Dosage: 25 mg/kg, 50 mg/kg MOTS-c (human) (saline)
Administration: Intraperitoneal injection, once daily, for 21 days starting 1 hour post-injury
Result: At 50 mg/kg, MOTS-c reduced neurological severity scores (NSS) by 45% and improved rotarod performance (latency increased by 50%) compared to injured controls.
Brain tissue analysis showed reduced HMGB1 expression (30% decrease), TLR4/NF-κB pathway inhibition, and lower pro-inflammatory cytokines (TNF-α, IL-6) in the ipsilateral cortex.
OBB-NC formulation (3 mg/kg) showed comparable effects with enhanced BBB penetration.
Animal Model: Male ICR mice (25-30 g, 6-week-old) with Formalin-induced paw inflammation model
Dosage: 50 mg/kg MOTS-c (human) (saline)
Administration: Intraperitoneal injection, 1 hour before formalin challenge, single dose
Result: Significantly reduced licking time in the late phase (phase II, 11-40 min) by 60% compared to vehicle controls.
Immunohistochemistry revealed decreased c-fos positive cells (40% reduction) in the spinal dorsal horn, with Western blot confirming suppressed phosphorylation of ERK (Thr202/Tyr204), JNK (Thr183/Tyr185), and P38 (Thr180/Tyr182) by 30-50%.
The AMPK inhibitor Compound C abolished these effects.
Animal Model: Male Sprague-Dawley rats (220-240 g, 7-week-old) with high-fat diet/streptozotocin-induced type 2 diabetes model
Dosage: 0.5 mg/kg MOTS-c (human) (saline)
Administration: Intraperitoneal injection, once daily, for 8 weeks
Result: Significantly decreased fasting blood glucose (FBG) by 35%, HOMA-IR by 40%, and plasma triglycerides (TG)/total cholesterol (TC) by 25-30% compared to diabetic controls.
Reduced mitochondrial swelling and cristae damage, with increased SOD/GSH activity and upregulated p-AMPK, Nrf2, and Keap1 protein expression in the heart.
Combined with exercise, MOTS-c further enhanced glucose disposal and attenuated oxidative stress (MDA reduction by 50%).
性状 固体
颜色 White to off-white

化学信息

分子量 2234.64
分子式 C103H156N28O24S2

储存&溶解度

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 5 mg/mL (2.24 mM)

DMSO 中的溶解度 : 4 mg/mL (1.79 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM0.4475 mL2.2375 mL4.4750 mL11.1875 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础